Press Enter to search · Shift+Enter for new line
Start from your perspective
Featured landscapes
200+ active trials across semaglutide, tirzepatide, and next-gen agents
Hematologic and solid tumor immunotherapy, Phase 1 through 3
Amyloid, tau, and lifestyle interventions across early and late stage
First-in-human and pivotal studies in rare disease and oncology
Orphan drug designations, small enrollment targets, high unmet need
Novel antibiotics and combination strategies against resistant pathogens
Pioneering targeted protein degradation: oral small molecules that destroy disease-causing proteins instead of just blocking them. Tackling historically undruggable targets in inflammation and oncology.
Pipeline programs
Pegasus™ Platform · PROTAC® & Molecular Glue Degraders · Live data from ClinicalTrials.gov & PubMed